Drug & supplement interaction

Transfer Factor + Trilaciclib Dihydrochloride

Trilaciclib Dihydrochloride brand name: Cosela.

No Known Interaction

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated July 2026 · Pair last verified Sep 27, 2026

The bottom line No known interaction

We found no known interaction between Transfer Factor and Trilaciclib Dihydrochloride in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share

Facebook Post Reddit Email

On this page

Interaction report

Transfer Factor and Trilaciclib Dihydrochloride

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Trilaciclib Dihydrochloride and Transfer Factor in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

Worth understanding: our licensed dataset holds no drug-interaction record for Transfer Factor at all — not against Trilaciclib Dihydrochloride, and not against any other medication we track. This verdict therefore rests on the absence of any recorded data, not on research that looked at this combination and found nothing. We cannot rule an interaction out.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Transfer Factor safety at a glance

Transfer Factor overall Use caution Generally well tolerated in studies, but long-term safety and product quality are not well established.

Pregnancy Avoid Safety has not been established, so it is best avoided during pregnancy.

Breastfeeding Avoid Not enough safety information exists, so avoid while breastfeeding.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Trilaciclib Dihydrochloride and Transfer Factor? Ask Dr. Brian Staiger, PharmD, BCPS directly ›

What to actually watch for

No Interaction Found — But Data Suggests Transfer Factor and Trilaciclib Dihydrochloride May Share a Side Effect

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do.

Tiredness Additional detail
Transfer Factor
“Orally or parenterally, transfer factor seems to be well tolerated. Adverse effects may include fever. Parenterally, transfer factor can cause nausea, fatigue, and tenderness, pain, and swelling at the injection site.”

Transfer Factor · Natural Medicines adverse-effect record, reported in acne.
6 sources cited

350. Jones JF, Minnich LL, Jeter WS, et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-4. PubMed

1445. Louie E, Borkowsky W, Klesius PH, et al. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol 1987;44:329-34. PubMed

1507. Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol 1989;29:475-516. PubMed

3062. Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed

3063. Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer 1983;51:269-72. PubMed

7562. Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203. PubMed
“Parenterally, fatigue has been reported for up to 4 hours in a patient using transfer factor.”

Transfer Factor · Natural Medicines adverse-effect record, reported in fatigue.
1 source cited

78789. Thestrup-Pedersen, K., Grunnet, E., and Zachariae, H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Derm.Venereol. 1982;62(1):47-53. DOI
Trilaciclib Dihydrochloride

Listed in the ADVERSE REACTIONS section of the FDA label for Trilaciclib Dihydrochloride. Read the label on DailyMed ›

Reported for Transfer Factor but not commonly for Trilaciclib Dihydrochloride: swelling, nausea, fever and acne.

Effects for Trilaciclib Dihydrochloride come from the ADVERSE REACTIONS section of its FDA label; effects for Transfer Factor come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Overlapping uses

What Trilaciclib Dihydrochloride Is Prescribed For, and What Transfer Factor Has Been Studied For

These two come up together because they touch the same health topic — not because they do the same job. Trilaciclib Dihydrochloride is a prescription medicine with approved uses on its FDA label. Transfer Factor is a supplement: what follows is what researchers have looked at it for, and how strong that evidence is.

Trilaciclib Dihydrochloride is prescribed for: Trilaciclib Injection (brand name Cosela) is used in adults with extensive-stage small cell lung cancer. It helps decrease the incidence of chemotherapy-induced myelosuppression. That means it lowers the chance that chemotherapy will suppress the bone marrow's production of blood cells. It is given before certain chemotherapy regimens: a platinum/etoposide-containing regimen or a topotecan-containing regimen.

Transfer Factor has been studied for:

Lung cancer studied, not established Transfer Factor has been studied for this. Natural Medicines rates the evidence: Possibly Ineffective Read what the research shows
Transfer Factor for lung cancer
Most research shows that administering human-derived transfer factor intramuscularly or subcutaneously, in combination with lung resection and chemotherapy, does not increase survival in patients with lung cancer. However, some preliminary evidence suggests that transfer factor might improve survival in lung cancer patients with Stage IIIA or IIIB disease.
4 sources cited

5447. Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992;53:391-6. PubMed

7800. Fujisawa T, Yamaguchi Y, Kimura H, et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984;54:663-9. PubMed

78793. Fujisawa, T., Yamaguchi, Y., Kimura, H., Arita, M., Shiba, M., and Baba, M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn.J.Surg. 1984;14(6):452-458. PubMed

78824. Pilotti, V., Mastrorilli, M., Pizza, G., De, Vinci C., Busutti, L., Palareti, A., Gozzetti, G., and Cavallari, A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996;9(1-3):117-121. PubMed

Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace Trilaciclib Dihydrochloride on your own; if you are taking Transfer Factor for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.

Everything else you take

See Every Supplement That Interacts With Trilaciclib Dihydrochloride

This page covers Transfer Factor only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Trilaciclib Dihydrochloride page lists 13 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: American Hellebore (major), Arsenic (major), Cesium (major), Ephedra (major) and Grapefruit (major).

By severity: 6 major · 7 moderate.

From our pharmacist’s overview on the Trilaciclib Dihydrochloride page

“Trilaciclib (Cosela) is an infusion given before chemotherapy to shield bone marrow in people with small cell lung cancer, and its supplement list deserves genuine attention because all 13 flagged ingredients press on the same weak point, the heart's electrical rhythm. Each can lengthen the QT interval, the pause between beats on an EC…”

Reviewed by 2 · Jul 18, 2026

Open the Trilaciclib Dihydrochloride interaction page

How much people look this up

Where Transfer Factor and Trilaciclib Dihydrochloride Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Transfer Factor

Top half

#627 of 1,452 supplements looked up here in the last 7 days

29 days ago today

Medication Trilaciclib Dihydrochloride

Steady interest

#2,156 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?

Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Transfer Factor reference on this page ↓
Freshness: we automatically re-check this combination every week — this pair was last verified September 27, 2026. The Transfer Factor and Trilaciclib Dihydrochloride records this page draws on were last updated July 10, 2026.
What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.

Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD, BCPS.

Supplement

About Transfer Factor

What is Transfer Factor?

Immune support
Preventing colds and infections
Allergies
General wellness
Chronic viral conditions

Transfer factors are small immune molecules taken from cow colostrum or egg yolk and sold as supplements meant to boost or 'train' the immune system. Solid human evidence for the supplement products is limited, and quality varies widely between brands. Talk with your pharmacist or doctor before using one, especially if you have an immune condition.

Small immune molecules (peptides) extracted from sources such as cow colostrum or hen egg yolk · Capsules, tablets, powders

An interaction check asks whether these two react with each other — it does not ask whether Transfer Factor is a good idea for someone in your situation. Here is what our Transfer Factor record says about it on its own.

Transfer Factor: dosing

There is no official or standardized dose for transfer factor supplements. Because products differ in how they are made and how concentrated they are, the right amount is hard to define.The safest approach is to follow the directions on the product label and not exceed the recommended amount. They can help you decide if a product is appropriate and reasonable.

From our Transfer Factor monograph — the full record covers uses, side effects and every documented interaction.

Read the full Transfer Factor monograph & all interactions

Medication

About Trilaciclib Injection

What Is Trilaciclib Injection Used For?

Brand name: Cosela

Trilaciclib Injection (brand name Cosela) is used in adults with extensive-stage small cell lung cancer. It helps decrease the incidence of chemotherapy-induced myelosuppression. That means it lowers the chance that chemotherapy will suppress the bone marrow's production of blood cells.

It is given before certain chemotherapy regimens: a platinum/etoposide-containing regimen or a topotecan-containing regimen.

See full Trilaciclib Injection drug information

Keep checking

Other Drugs & Transfer Factor

Browse every other medication we’ve checked against Transfer Factor — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major

0Moderate

0Minor

2,829No known interaction

2,829 No interaction

No interaction 2,829 drugs checked — show the list

We also checked Transfer Factor against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,829 medications checked with no known interaction — see the full Transfer Factor list.

See the full Transfer Factor interactions page

See every supplement checked against Trilaciclib Dihydrochloride, ranked by severity

Evidence & sources

Transfer Factor References

The 49 references that drive our Transfer Factor monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Jones JF, Minnich LL, Jeter WS, et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-4. PubMed
Steele RW, Myers MG, Vincent MM. Transfer factor for the prevention of varicella-zoster infection in childhood leukemia. N Engl J Med 1980;303:355-9. PubMed
Louie E, Borkowsky W, Klesius PH, et al. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol 1987;44:329-34. PubMed
McMeeking A, Borkowsky W, Klesius PH, et al. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infect Dis 1990;161:108-12. PubMed
Fudenberg HH. Transfer factor: past, present and future. Annu Rev Pharmacol Toxicol 1989;29:475-516. PubMed
Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
Miller LL, Spitler LE, Allen RE, Minor DR. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 1988;61:1543-9. PubMed
Bukowski RM, Deodhar S, Hewlett JS, Greenstreet R. Randomized controlled trial of transfer factor in Stage II malignant melanoma. Cancer 1983;51:269-72. PubMed
Bowden RA, Siegel MS, Steele RW, et al. Immunologic and clinical responses to varicella-zoster virus-specific transfer factor following marrow ransplantation. J Infect Dis 1985;152:1324-7.
Sharma MK, Anaraki F, Ala F. Preliminary results of transfer factor therapy of persistant cutaneous leishmania infection. Clin Immunol Immunopathol 1979;12:183-90. PubMed
Whyte RI, Schork MA, Sloan H, et al. Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up. Ann Thorac Surg 1992;53:391-6. PubMed
Lloyd AR, Hickie I, Brockman A, et al. Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94:197-203. PubMed
Spitler LE. Transfer factor therapy in the Wiskott-Aldrich syndrome. Results of long-term follow-up in 32 patients. Am J Med 1979;67:59-66.
Roda E, Viza D, Pizza G, et al. Transfer factor for the treatment of HBsAg-positive chronic active hepatitis. Proc Soc Exp Biol Med 1985;178:468-75. PubMed
Basten A, McLeod JG, Pollard JD, et al. Transfer factor in treatment of multiple sclerosis. Lancet 1980;2:931-4. PubMed
Fog T, Pedersen L, Raun NE, et al. Long-term transfer-factor treatment for multiple sclerosis. Lancet 1978;1:851-3. PubMed
Fujisawa T, Yamaguchi Y, Kimura H, et al. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984;54:663-9. PubMed
Delgado O, Romano EL, Belfort E, et al. Dialyzable leukocyte extract therapy in immunodepressed patients with cutaneous leishmaniasis. Clin Immunol Immunopathol 1981;19:351-9. PubMed
Stevens, D. A., Ferrington, R. A., Merigan, T. C., and Marinkovich, V. A. Randomized trial of transfer factor treatment of human warts. Clin.Exp.Immunol. 1975;21(3):520-524.
Iseki, M., Aoyama, T., Koizumi, Y., Ojima, T., Murase, Y., and Osano, M. [Effects of transfer factor on chronic hepatitis B in childhood]. Kansenshogaku Zasshi 1989;63(12):1329-1332. PubMed
Corrado, F., Pizza, G., De, Vinci C., and Corrado, G. [Immunotherapy with transfer factor in hormone-resistant metastasized carcinoma of the prostate]. Arch.Esp.Urol. 1989;42 Suppl 2:191-196.
No author. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group. J.Neurol.Neurosurg.Psychiatry 1989;52(5):566-574. PubMed
Ashorn, R., Uotila, A., Kuokkanen, K., Rasanen, L., Karhumaki, E., and Krohn, K. Cellular immunity in acne vulgaris during transfer factor treatment. Ann.Clin.Res. 1985;17(4):152-155.
Goldenberg, G. J., Brandes, L. J., Lau, W. H., Miller, A. B., Wall, C., and Ho, J. H. Cooperative trial of immunotherapy for nasopharyngeal carcinoma with transfer factor from donors with Epstein-Barr virus antibody activity. Cancer Treat.Rep. 1985;69(7-
Hancock, B. W., Bruce, L., Sokol, R. J., and Clark, A. Transfer factor in Hodgkin's disease: a randomized clinical and immunological study. Eur.J.Cancer Clin.Oncol. 1988;24(5):929-933. PubMed
Miller, L. L., Spitler, L. E., Allen, R. E., and Minor, D. R. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer 4-15-1988;61(8):1543-1549. PubMed
Wagner, G., Knapp, W., Gitsch, E., and Selander, S. Transfer factor for adjuvant immunotherapy in cervical cancer. Cancer Detect.Prev.Suppl 1987;1:373-376.
Gilchrist, G. S., Ivins, J. C., Ritts, R. E., Jr., Pritchard, D. J., Taylor, W. F., and Edmonson, J. M. Adjuvant therapy for nonmetastatic osteogenic sarcoma: an evaluation of transfer factor versus combination chemotherapy. Cancer Treat.Rep. 1978;62(2):
Hoyeraal, H. M., Froland, S. S., Salvesen, C. F., Munthe, E., Natvig, J. B., Kass, E., Blichfeldt, P., Hegna, T. M., Revlem, E., Sandstad, B., and Hjort, N. L. No effect of transfer factor in juvenile rheumatoid arthritis by double-blind trial. Ann.Rheum
Vicary, F. R., Chambers, J. D., and Dhillon, P. Double-blind trial of the use of transfer factor in the treatment of Crohn's disease. Gut 1979;20(5):408-413. PubMed
Ashorn, R. G., Rasanen, L., Marnela, K. M., and Krohn, K. J. Human transfer factor in vitro. II. Augmentation of the secretion of leucocyte migration inhibitory factor (LIF) by leucocyte dialysate and by its components L-serine and glycine. Clin.Exp.Immu
Olarte, M. R., Gersten, J. C., Zabriskie, J., and Rowland, L. P. Transfer factor is ineffective in amyotrophic lateral sclerosis. Ann.Neurol. 1979;5(4):385-388. PubMed
Shulman, S. T., Hutto, J. H., Jr., Ayoub, E. M., Howlett, S. A., Scott, B., and McGuigan, J. E. A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis: preliminary report of efficacy. Cell Immunol. 3-15-1979;4 PubMed
Ellis-Pegler, R., Sutherland, D. C., Douglas, R., Woodfield, D. G., and Wilson, J. D. Transfer factor and hepatitis B: a double blind study. Clin.Exp.Immunol. 1979;36(2):221-226.
Thestrup-Pedersen, K., Grunnet, E., and Zachariae, H. Transfer factor therapy in mycosis fungoides: a double-blind study. Acta Derm.Venereol. 1982;62(1):47-53. DOI
Fujisawa, T., Yamaguchi, Y., Kimura, H., Arita, M., Shiba, M., and Baba, M. Randomized controlled trial of transfer factor immunochemotherapy as an adjunct to surgical treatment for primary adenocarcinoma of the lung. Jpn.J.Surg. 1984;14(6):452-458. PubMed
Lamoureux, G., Cosgrove, J., Duquette, P., Lapierre, Y., Jolicoeur, R., and Vanderland, F. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin.Exp.Immunol. 1981;43(3):557-564.
Pizza, G., Meduri, R., De, Vinci C., Scorolli, L., and Viza, D. Transfer factor prevents relapses in herpes keratitis patients: a pilot study. Biotherapy 1994;8(1):63-68. PubMed
Fernandez, O., Diaz, N., Morales, E., Toledo, J., Hernandez, E., Rojas, S., Madriz, X., and Lopez, Saura P. Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias. Br.J.Haematol. 1993;84(3):423-427 PubMed
Raise, E., Guerra, L., Viza, D., Pizza, G., De, Vinci C., Schiattone, M. L., Rocaccio, L., Cicognani, M., and Gritti, F. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV). Biotherapy 1996;9(1-3):49-54. PubMed
Meduri, R., Campos, E., Scorolli, L., De, Vinci C., Pizza, G., and Viza, D. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 1996;9(1-3):61-66. PubMed
Pizza, G., Viza, D., De, Vinci C., Palareti, A., Cuzzocrea, D., Fornarola, V., and Baricordi, R. Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy 1996;9(1-3):67-72. PubMed
Byston, J., Cech, K., Pekarek, J., and Jilkova, J. Effect of anti-herpes specific transfer factor. Biotherapy 1996;9(1-3):73-75. PubMed
De Vinci, C., Levine, P. H., Pizza, G., Fudenberg, H. H., Orens, P., Pearson, G., and Viza, D. Lessons from a pilot study of transfer factor in chronic fatigue syndrome. Biotherapy 1996;9(1-3):87-90. PubMed
Prasad, U., bin Jalaludin, M. A., Rajadurai, P., Pizza, G., De, Vinci C., Viza, D., and Levine, P. H. Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study. Biotherapy 1996;9(1-3):109-115. PubMed
Pilotti, V., Mastrorilli, M., Pizza, G., De, Vinci C., Busutti, L., Palareti, A., Gozzetti, G., and Cavallari, A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996;9(1-3):117-121. PubMed
Pizza, G., De, Vinci C., Cuzzocrea, D., Menniti, D., Aiello, E., Maver, P., Corrado, G., Romagnoli, P., Dragoni, E., LoConte, G., Riolo, U., Palareti, A., Zucchelli, P., Fornarola, V., and Viza, D. A preliminary report on the use of transfer factor for t
Acosta-Rios MP, Sauer-Ramírez E, Castro-Muñoz LJ, et al. Effect of dialyzable leukocyte extract on chronic cervicitis in patients with HPV infection. J Med Life. 2017;10(4):237-243.
Rodriguez-Flores A, Nuñez-Fernandez G, Estrada-Garcia I, et al. Adjuvant treatment with a dialyzable leukocytes extract contributes to maintain HPV-infected women free of low-grade cervical lesions. Eur J Gynaecol Oncol. 2015;36(6):655-61.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Transfer Factor and Trilaciclib Dihydrochloride Together: Common Questions

Is it safe to take Transfer Factor with Trilaciclib Dihydrochloride?

We do not list a known interaction between Transfer Factor and Trilaciclib Dihydrochloride. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.

Do Transfer Factor and Trilaciclib Dihydrochloride have any of the same side effects?

Yes — our sources link each of them separately to one of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.

Are Transfer Factor and Trilaciclib Dihydrochloride used for the same thing?

They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Transfer Factor in each. That is a conversation for your prescriber, especially if Trilaciclib Dihydrochloride is being adjusted to a target.

Does Trilaciclib Dihydrochloride interact with any supplements?

Yes. Trilaciclib Dihydrochloride has documented interactions with 13 supplements in our database — Transfer Factor is not one of them. The Trilaciclib Dihydrochloride interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Transfer Factor monograph Uses, safety profile, and every drug interaction in one place Trilaciclib Injection drug information The full plain-English guide to this medication Trilaciclib Dihydrochloride supplement interactions Every supplement checked against Trilaciclib Dihydrochloride, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 49 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Trilaciclib Dihydrochloride and Transfer Factor?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.